Prevalence of genosubtypes (PorA types) of serogroup B invasive meningococcus in the north of Spain from 2000 to 2003

References

1. Abdillahi H., Poolman J. T. 1987; Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 48:367–371 [CrossRef]
   [Google Scholar]
2. Abdillahi H., Poolman J. T. 1988; Definition of meningococcal class 1 OMP subtyping antigens by monoclonal antibodies. FEMS Microbiol Immunol 1:139–144
   [Google Scholar]
3. Bjune G., Hoiby E. A., Gronnesby J. K. & 14 other authors; 1991; Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093–1096 [CrossRef]
   [Google Scholar]
4. Clarke S. C., Diggle M. A., Molling P., Unemo M., Olcen P. 2003; Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?. Vaccine 21:2468–2473 [CrossRef]
   [Google Scholar]
5. de Kleijn E. D., de Groot R., Labadie J. & 9 other authors; 2000; Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18:1456–1466 [CrossRef]
   [Google Scholar]
6. de Kleijn E. D., van Eijndhoven L., Vermont C., Kuipers B., van Dijken H., Rumke H., de Groot R., van Alphen L., van den Dobbelsteen G. 2002; Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20:352–358
   [Google Scholar]
7. de Moraes J. C., Perkins B. A., Camargo M. C. & 9 other authors; 1992; Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:1074–1078 [CrossRef]
   [Google Scholar]
8. Diggle M. A., Clarke S. C. 2003; Detection and genotyping of meningococci using a nested PCR approach. J Med Microbiol 52:51–57 [CrossRef]
   [Google Scholar]
9. Feavers I. M., Suker J., McKenna A. J., Heath A. B., Maiden M. C. 1992; Molecular analysis of the serotyping antigens of Neisseria meningitidis . Infect Immun 60:3620–3629
   [Google Scholar]
10. Feavers I. M., Fox A. J., Gray S., Jones D. M., Maiden M. C. 1996; Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 3:444–450
    [Google Scholar]
11. Frasch C. E., van Alphen L., Holst J., Poolman J. T., Rosenqvist E. 2001; Outer membrane protein vesicle vaccines for meningococcal disease. In Meningococcal Vaccines pp 81–107 Edited by Pollard A. J., Maiden M. C. Totowa: Humana Press;
    [Google Scholar]
12. Martin S. L., Borrow R., van der Ley P., Dawson M., Fox A. J., Cartwright K. A. 2000; Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18:2476–2481 [CrossRef]
    [Google Scholar]
13. McGuinness B. T., Lambden P. R., Heckels J. E. 1993; Class 1 outer membrane protein of Neisseria meningitidis : epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol Microbiol 7:505–514 [CrossRef]
    [Google Scholar]
14. Norheim G., Arne Hoiby E., Caugant D. A., Namork E., Tangen T., Fritzsonn E., Rosenqvist E. 2004; Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 22:2171–2180 [CrossRef]
    [Google Scholar]
15. Perez-Trallero E., Vicente D., Montes M., Cisterna R. 2002; Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis . Lancet 360:953– 953
    [Google Scholar]
16. Rosenqvist E., Hoiby E. A., Wedege E., Bryn K., Kolberg J., Klem A., Ronnild E., Bjune G., Nokleby H. 1995; Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63:4642–4652
    [Google Scholar]
17. Russell J. E., Jolley K. A., Feavers I. M., Maiden M. C., Suker J. 2004; PorA variable regions of Neisseria meningitidis . Emerg Infect Dis 10:674–678 [CrossRef]
    [Google Scholar]
18. Sacchi C. T., Lemos A. P., Brandt M. E., Whitney A. M., Melles C. E., Solari C. A., Frasch C. E., Mayer L. W. 1998; Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5:845–855
    [Google Scholar]
19. Sacchi C. T., Whitney A. M., Popovic T. & 7 other authors; 2000; Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992–1998. J Infect Dis 182:1169–1176 [CrossRef]
    [Google Scholar]
20. Sacchi C. T., Lemos A. P., Popovic T. & 8 other authors; 2001; Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development. J Clin Microbiol 39:2897–2903 [CrossRef]
    [Google Scholar]
21. Vermont C. L., van Dijken H. H., Kuipers A. J., van Limpt C. J., Keijzers W. C., van der Ende A., de Groot R., van Alphen L., van den Dobbelsteen G. P. 2003; Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 71:1650–1655 [CrossRef]
    [Google Scholar]
22. Vogel U., Claus H. 2003; Molecular epidemiology of Neisseria meningitidis . Front Biosci 8:e14–e22 [CrossRef]
    [Google Scholar]